[144] Jade Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 Notice of Proposed Sale filed by Jade Biosciences (NASDAQ: JBIO) on June 28, 2025, detailing planned insider stock sales. The filing indicates a proposed sale of 235 shares with an aggregate market value of $2,462.80 through Merrill Lynch, representing a small portion of the total 28,985,019 shares outstanding.

Key transaction details:

• Shares were originally acquired through Private Placement on June 4, 2021
• Planned sale date: June 25, 2025
• Current market price implies approximately $10.48 per share

Recent insider selling activity by Atlas Ventures entities in the past 3 months totals 51,171 shares for aggregate proceeds of $537,316.10, including significant sales by Atlas Ventures Fund XII LP (50,992 shares) and smaller transactions by Atlas Venture Associates XII, LP (179 shares). This Form 144 filing suggests continued insider selling pressure while affirming no knowledge of undisclosed material adverse information.

Positive

• None.

Negative

• Venture capital firms Atlas Ventures Fund XII LP and Atlas Venture Associates XII LP have sold a significant total of 51,171 shares over the past 3 months, with accelerating selling volume in June 2025 (45,240 shares), indicating potential loss of institutional confidence

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Jade Biosciences, Inc.	Merrill Lynch One Bryant Park New York NY 10036	235	2462.80	28985019	06/25/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2021	Private Placement	Issuer			235	06/04/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Ventures Fund XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	05/06/2025	5883	64061.73
Atlas Venture Associates XII, LP 300 Technology Sq Ste 8, Cambridge MA 02139	Common	05/06/2025	48	498.84
Atlas Ventures Fund XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	06/24/2025	16132	167776.03
Atlas Venture Associates XII, LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	06/24/2025	131	1300.54
Atlas Ventures Fund XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	06/25/2025	28977	303678.96

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares of JBIO stock are being proposed for sale in the latest Form 144 filing?

According to the Form 144 filing dated June 28, 2025, 235 shares of Jade Biosciences, Inc. (JBIO) are proposed to be sold through Merrill Lynch, with an aggregate market value of $2,462.80.

What is the total number of JBIO shares outstanding as of June 2025?

As disclosed in the Form 144 filing, Jade Biosciences, Inc. (JBIO) has 28,985,019 shares outstanding as of the filing date.

How many JBIO shares did Atlas Ventures Fund XII LP sell in the past 3 months?

Atlas Ventures Fund XII LP made three significant sales in the past 3 months: 5,883 shares on May 6, 2025, 16,132 shares on June 24, 2025, and 28,977 shares on June 25, 2025, totaling 50,992 shares with combined gross proceeds of approximately $535,516.72.

When were the JBIO shares originally acquired by the seller?

The shares were originally acquired on June 4, 2021, through a Private Placement transaction with the issuer. The acquisition was paid for in cash on the same date.

What is the proposed date of sale for the JBIO shares in this Form 144?

The Form 144 filing indicates that the approximate date of sale for the 235 JBIO shares is June 25, 2025, and they will be sold on the Nasdaq exchange.